Literature DB >> 27191182

Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance.

Trang T Ly1,2, Stuart A Weinzimer3, David M Maahs4, Jennifer L Sherr3, Anirban Roy5, Benyamin Grosman5, Martin Cantwell5, Natalie Kurtz5, Lori Carria3, Laurel Messer4, Rie von Eyben1, Bruce A Buckingham1.   

Abstract

BACKGROUND: Automated insulin delivery systems, utilizing a control algorithm to dose insulin based upon subcutaneous continuous glucose sensor values and insulin pump therapy, will soon be available for commercial use. The objective of this study was to determine the preliminary safety and efficacy of initialization parameters with the Medtronic hybrid closed-loop controller by comparing percentage of time in range, 70-180 mg/dL (3.9-10 mmol/L), mean glucose values, as well as percentage of time above and below target range between sensor-augmented pump therapy and hybrid closed-loop, in adults and adolescents with type 1 diabetes.
METHODS: We studied an initial cohort of 9 adults followed by a second cohort of 15 adolescents, using the Medtronic hybrid closed-loop system with the proportional-integral-derivative with insulin feed-back (PID-IFB) algorithm. Hybrid closed-loop was tested in supervised hotel-based studies over 4-5 days.
RESULTS: The overall mean percentage of time in range (70-180 mg/dL, 3.9-10 mmol/L) during hybrid closed-loop was 71.8% in the adult cohort and 69.8% in the adolescent cohort. The overall percentage of time spent under 70 mg/dL (3.9 mmol/L) was 2.0% in the adult cohort and 2.5% in the adolescent cohort. Mean glucose values were 152 mg/dL (8.4 mmol/L) in the adult cohort and 153 mg/dL (8.5 mmol/L) in the adolescent cohort.
CONCLUSIONS: Closed-loop control using the Medtronic hybrid closed-loop system enables adaptive, real-time basal rate modulation. Initializing hybrid closed-loop in clinical practice will involve individualizing initiation parameters to optimize overall glucose control.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  artificial pancreas; continuous glucose monitoring; hybrid closed loop; type 1 diabetes

Mesh:

Substances:

Year:  2016        PMID: 27191182     DOI: 10.1111/pedi.12399

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  22 in total

1.  Incorporating Unannounced Meals and Exercise in Adaptive Learning of Personalized Models for Multivariable Artificial Pancreas Systems.

Authors:  Iman Hajizadeh; Mudassir Rashid; Kamuran Turksoy; Sediqeh Samadi; Jianyuan Feng; Mert Sevil; Nicole Hobbs; Caterina Lazaro; Zacharie Maloney; Elizabeth Littlejohn; Ali Cinar
Journal:  J Diabetes Sci Technol       Date:  2018-07-31

2.  Controlling the AP Controller: Controller Performance Assessment and Modification.

Authors:  Iman Hajizadeh; Nicole Hobbs; Sediqeh Samadi; Mert Sevil; Mudassir Rashid; Rachel Brandt; Mohammad Reza Askari; Zacharie Maloney; Ali Cinar
Journal:  J Diabetes Sci Technol       Date:  2019-09-27

3.  Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System.

Authors:  Esti Iturralde; Molly L Tanenbaum; Sarah J Hanes; Sakinah C Suttiratana; Jodie M Ambrosino; Trang T Ly; David M Maahs; Diana Naranjo; Natalie Walders-Abramson; Stuart A Weinzimer; Bruce A Buckingham; Korey K Hood
Journal:  Diabetes Educ       Date:  2017-04       Impact factor: 2.140

4.  Feasibility Studies of an Insulin-Only Bionic Pancreas in a Home-Use Setting.

Authors:  Laya Ekhlaspour; Laura M Nally; Firas H El-Khatib; Trang T Ly; Paula Clinton; Eliana Frank; Molly L Tanenbaum; Sarah J Hanes; Rajendranath R Selagamsetty; Korey Hood; Edward R Damiano; Bruce A Buckingham
Journal:  J Diabetes Sci Technol       Date:  2019-08-30

5.  Plasma-Insulin-Cognizant Adaptive Model Predictive Control for Artificial Pancreas Systems.

Authors:  Iman Hajizadeh; Mudassir Rashid; Ali Cinar
Journal:  J Process Control       Date:  2019-04-10       Impact factor: 3.666

6.  Trust in hybrid closed loop among people with diabetes: Perspectives of experienced system users.

Authors:  Molly L Tanenbaum; Esti Iturralde; Sarah J Hanes; Sakinah C Suttiratana; Jodie M Ambrosino; Trang T Ly; David M Maahs; Diana Naranjo; Natalie Walders-Abramson; Stuart A Weinzimer; Bruce A Buckingham; Korey K Hood
Journal:  J Health Psychol       Date:  2017-07-12

7.  Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia.

Authors:  Eyal Dassau; Jordan E Pinsker; Yogish C Kudva; Sue A Brown; Ravi Gondhalekar; Chiara Dalla Man; Steve Patek; Michele Schiavon; Vikash Dadlani; Isuru Dasanayake; Mei Mei Church; Rickey E Carter; Wendy C Bevier; Lauren M Huyett; Jonathan Hughes; Stacey Anderson; Dayu Lv; Elaine Schertz; Emma Emory; Shelly K McCrady-Spitzer; Tyler Jean; Paige K Bradley; Ling Hinshaw; Alejandro J Laguna Sanz; Ananda Basu; Boris Kovatchev; Claudio Cobelli; Francis J Doyle
Journal:  Diabetes Care       Date:  2017-10-13       Impact factor: 19.112

Review 8.  Sleep in Type 1 Diabetes: Implications for Glycemic Control and Diabetes Management.

Authors:  Katia M Perez; Emily R Hamburger; Morgan Lyttle; Rodayne Williams; Erin Bergner; Sachini Kahanda; Erin Cobry; Sarah S Jaser
Journal:  Curr Diab Rep       Date:  2018-02-05       Impact factor: 4.810

9.  MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy.

Authors:  Aria Saunders; Laurel H Messer; Gregory P Forlenza
Journal:  Expert Rev Med Devices       Date:  2019-09-30       Impact factor: 3.166

10.  In-home nighttime predictive low glucose suspend experience in children and adults with type 1 diabetes.

Authors:  Laurel H Messer; Peter Calhoun; Bruce Buckingham; Darrell M Wilson; Irene Hramiak; Trang T Ly; Marsha Driscoll; Paula Clinton; David M Maahs
Journal:  Pediatr Diabetes       Date:  2016-04-29       Impact factor: 4.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.